

### ADDITIONAL INFORMATION TO PRIOR ANNOUNCEMENT

**MELBOURNE (AUSTRALIA) 29 November 2019:** At the request of ASX, Invion Limited (ASX: IVX) ("Invion" or "Company") provides the following additional information to the announcement released on 27 November 2019 entitled "Photosoft technology shrinks ovarian cancer by more than half in pre-clinical trial":

1. There is no significance in the difference between the terms "pre-clinical trial" as used in the announcement title and "pre-clinical study" as used in the body of the announcement.
2. The pre-clinical study was undertaken in a syngeneic primary ovarian cancer mouse model as established and previously used in pre-clinical studies at the Hudson Institute. The presence of ovarian cancer in the mice was confirmed prior to use in the study. 48 mice with primary ovarian tumours were used in the study. The study was not powered for statistical significance and no statistical analysis was undertaken. The study included appropriate controls involving no treatment of a control group of the ovarian cancer mice.

---

#### Investor enquiries

Managing Director & CEO, Craig Newton

T: +61 3 9081 6005

E: [investor@inviongroup.com](mailto:investor@inviongroup.com)

#### Media enquiries

Brendon Lau

T: 0409 341 613

E: [brendon@vantagepointpartners.com.au](mailto:brendon@vantagepointpartners.com.au)

#### About Invion

Invion is a drug delivery company that is leading the global research and development of Photosoft™ technology for the treatment of a range of cancers. Invion holds the Australia and New Zealand license rights to the Photosoft™ Technology. Research and clinical trials are funded by the technology licensor, The Cho Group, via an R&D services agreement with the Company. Invion is listed on ASX (ASX:IVX). For further information please contact [investor@inviongroup.com](mailto:investor@inviongroup.com).

#### About Hudson Institute of Medical Research

Hudson Institute is a leading Australian medical research institute recognised internationally for discovery science and translational research into cancer, inflammation, reproductive health and pregnancy and infant and child health.

## **ASX ANNOUNCEMENT**

Our 475 scientists study human health and disease at a molecular and cellular level to discover how biological systems work and how disease and disability can be prevented or treated. Our close ties with clinicians and industry give us the ability to translate our discoveries into new preventative approaches, therapies and devices for patients.

We are a founding member of the Monash Health Translation Precinct with partners Monash Health and Monash University. Our integrated research teams include clinicians, nurses and clinical trial coordinators who both inform research programs based on patient need and advance these discoveries back to the clinic.

Working alongside clinicians in Melbourne hospitals for more than 50 years, Hudson Institute scientists pioneered IVF and stem cell discoveries and are now leading developments in paediatric cancer and the human microbiome. Our worldwide scientific and medical collaborations provide a foundation for transformative healthcare programs across the globe.

### **About Photodynamic Therapy (PDT)**

Invion is developing Photosoft™ technology as an improved next generation Photodynamic Therapy. PDT uses non-toxic photosensitisers and visible light in combination with oxygen to produce cytotoxic-reactive oxygen that kills malignant cells, shuts down tumours and stimulates the immune system. A potential alternative to surgery, and in contrast to radiotherapy and chemotherapy which are mostly immunosuppressive, PDT causes acute inflammation, expression of heat-shock proteins, and invasion and infiltration of a tumour by leukocytes.